Ayala Pharmaceuticals Inc.

10.45-0.0500-0.48%Vol 13.86K1Y Perf -30.81%
Apr 16th, 2021 16:00 DELAYED
BID10.60 ASK10.70
Open10.70 Previous Close10.50
Pre-Market- After-Market-
 - -  - -%
Target Price
23.08 
Analyst Rating
Moderate Buy 1.75
Potential %
120.86 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★ —    62.18
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap137.63M 
Earnings Rating
Price Range Ratio 52W %
9.12 
Earnings Date
30th Mar 2021

Today's Price Range

10.4010.88

52W Range

8.6228.68

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Strong Sell
Performance
1 Week
-3.69%
1 Month
-23.16%
3 Months
-19.24%
6 Months
-20.53%
1 Year
-30.81%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AYLA10.45-0.0500-0.48
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.58-0.73-25.86
Q03 2020-0.59-0.590.00
Q02 2020-0.53-0.74-39.62
Q01 2020-0.88-1.32-50.00
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.58
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume13.86K
Shares Outstanding13.17M
Trades Count122
Dollar Volume229.37K
Avg. Volume35.00K
Avg. Weekly Volume12.65K
Avg. Monthly Volume20.22K
Avg. Quarterly Volume39.01K

Ayala Pharmaceuticals Inc. (NASDAQ: AYLA) stock closed at 10.45 per share at the end of the most recent trading day (a -0.48% change compared to the prior day closing price) with a volume of 13.86K shares and market capitalization of 137.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Ayala Pharmaceuticals Inc. CEO is Roni Mamluk.

The one-year performance of Ayala Pharmaceuticals Inc. stock is -30.81%, while year-to-date (YTD) performance is -5%. AYLA stock has a five-year performance of %. Its 52-week range is between 8.62 and 28.68, which gives AYLA stock a 52-week price range ratio of 9.12%

Ayala Pharmaceuticals Inc. currently has a PE ratio of -4.20, a price-to-book (PB) ratio of 3.74, a price-to-sale (PS) ratio of 52.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -91.52%, a ROC of -55.22% and a ROE of 11 550.20%. The company’s profit margin is -%, its EBITDA margin is -828.30%, and its revenue ttm is $2.71 Million , which makes it $0.21 revenue per share.

Of the last four earnings reports from Ayala Pharmaceuticals Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.58 for the next earnings report. Ayala Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Ayala Pharmaceuticals Inc. is Moderate Buy (1.75), with a target price of $23.08, which is +120.86% compared to the current price. The earnings rating for Ayala Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ayala Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ayala Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.70, ATR14 : 1.33, CCI20 : -49.63, Chaikin Money Flow : -0.17, MACD : -1.40, Money Flow Index : 42.56, ROC : -2.52, RSI : 39.34, STOCH (14,3) : 29.68, STOCH RSI : 0.59, UO : 41.90, Williams %R : -70.32), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ayala Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
0
0
Moderate Buy
1 (25.00 %)
0
0
Hold
1 (25.00 %)
0
0
Moderate Sell
0 (0.00 %)
0
0
Strong Sell
0 (0.00 %)
0
0
Summary RatingModerate Buy
1.75
--

Ayala Pharmaceuticals Inc.

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

CEO: Roni Mamluk

Telephone: +972 83731541

Address: Oppenheimer 4, Rehovot 7670104, , IL

Number of employees: 31

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

73%27%

Bearish Bullish

56%44%

Bearish Bullish

59%41%

News

Stocktwits